CGL
MRNA icon

Clarius Group LLC’s Moderna MRNA Stock Holding History

Clarius Group LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,347
Closed -$279K – 467
2024
Q2 		$279K Buy
2,347
+54
+2% +$6.83K 0.02% 327
2024
Q1 		$244K Sell
2,293
-450
-16% -$45.4K 0.02% 400
2023
Q4 		$273K Buy
+2,743
New +$231K 0.02% 380
2023
Q3 		– Sell
-2,445
Closed -$297K – 501
2023
Q2 		$297K Sell
2,445
-366
-13% -$48.8K 0.02% 393
2023
Q1 		$432K Sell
2,811
-310
-10% -$51.1K 0.04% 289
2022
Q4 		$561K Sell
3,121
-75
-2% -$12.3K 0.05% 226
2022
Q3 		$378K Sell
3,196
-177
-5% -$26.9K 0.04% 280
2022
Q2 		$482K Buy
3,373
+806
+31% +$115K 0.05% 224
2022
Q1 		$652K Hold
2,567
– – 0.05% 190
2021
Q4 		$652K Buy
2,567
+1,708
+199% +$499K 0.05% 190
2021
Q3 		$331K Buy
+859
New +$317K 0.03% 298

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Clarius Group LLC's MRNA Position: Q3 2024 in Review

Clarius Group LLC sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,347 shares — an estimated $279K sold.

Clarius Group LLC first reported a position in MRNA in Q3 2021 and held it in 11 quarters. The position peaked at $652K in Q1 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Clarius Group LLC reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Clarius Group LLC sold 2,347 Moderna shares in Q3 2024, an estimated $279K.
  • Clarius Group LLC first reported a position in Moderna in Q3 2021 and held it in 11 quarters.
  • Clarius Group LLC's Moderna position peaked at $652K in Q1 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Clarius Group LLC's 13F filing for Q3 2024, filed 9 Oct 2024.